REVLIMID in combination with bortezomib
and dexamethasone (RVd), is now indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib
resistance in multiple myeloma.
A Phased Desensitization Protocol With Rituximab and Bortezomib
for Highly Sensitized Kidney Transplant Candidates.
Overall, we found that the ORR of patients treated with bortezomib
combination regimens was 95.5% (85/89) including 52.8% (47/89) CR, 16.8% (15/89) VGPR, and 23.6% (27/89) PR.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib
14.29% received steroid just prior to or along with bortezomib
. 14.29% were receiving concurrent chemotherapy.
Another problem is that drugs tested and proven in relapsed MM, such as the proteasome inhibitors (bortezomib
, carfilzomib, and ixazomib), cannot cross the blood-brain barrier, and standard chemotherapy drugs used to treat CNS lymphoma and brain cancer are not particularly effective in MM.
The combination of bortezomib
with the HDACi LBH589 (panobinostat) further increased cell killing in KLE cells (R175H GOF) as compared to bortezomib
alone (Figure 2(a)).
Abbreviations MM - multiple myeloma SCT - stem cell transplantation ASCT - autologous stem cell transplantation MPV - Melphalan, Bortezomib
, Pronison MPT - Melphalan, Thalidomide, Pronison BP - Bendamustine, Pronison VCD - Bortezomib
, Cyclophosphamide, Dexasone VTD - Bortezomib
, Cyclophosphamide, Dexasone PAD - Bortezomib
, Doxorubicin, Dexasone RVD - Bortezomib
, Lenalidomide, Dexasone R-ISS - Revised International Staging System OS - overall survival PFS - progression free survival IMiD - immunomodulatory imide drug LDH - lactate dehydrogenase Aim of this study was to define prognostic factors affecting overall survival in Bence-Jones multiple myeloma patients.
The mean number of bortezomib
cycles was 6.07[+ or -]1.06 in MF-MM and 6.73[+ or -]0.49 in classic MM group (NS).
Over the last years monoclonal antibodies directed against B cells (rituximab) as well as inhibitors of the proteasome (bortezomib
) have expanded our therapeutic repertoire .
reported 12 patents with MM who all received ASCT (2 of whom were on Bortezomib
therapy) and all developed HBV reactivation .
Because the patient was symptomatic with severe anemia (hemoglobin 5.6g/dL), he was started on chemotherapy with bortezomib
, dexamethasone, and rituximab (BDR) with bortezomib
1.3 mg/[m.sup.2] subcutaneously and dexamethasone 40 mg orally on days 1,4, 8, and 11, and rituximab 375 mg/[m.sup.2] on day 11 with cycles repeated on a 21-day schedule based on the high response rates reported by Dimopoulos et al.
Recently, there are few reports of the use of Bortezomib
for the treatment of LCDD [2, 4-6].
Ante la sospecha diagnostica de rinon de mieloma se instaura terapia con HFRsupra anadiendo tratamiento con esteroides y Bortezomib
, una vez confirmado el diagnostico.